ArticleDiscover oncology2025
Global trend and geographic distribution of thyroid cancer from 1990 to 2021 and its prediction until 2030.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A combined genetic and bioinformatic analysis implicates the CDKN1A rs1059234 variant in differentiated thyroid carcinoma susceptibility.Archives of endocrinology and metabolism · 2026Article
- Article
- Establishment and clinical performance evaluation of the thyroglobulin colloidal gold immunochromatographic assay.Frontiers in oncology · 2026Article
- Global and Regional Trends in Multiple Sclerosis Incidence with Projections to 2030: A Joinpoint Regression Analysis of the GBD Data 2021 by Socio-Demographic Index and WHO Regions.Annals of global health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThis study aimed to determine global thyroid cancer incidence and mortality trends from 1990 to 2021 and their projections for 2030.
methodsThis ecological study extracted data on global thyroid cancer incidence and mortality from 1990 to 2021 from the Global Burden of Disease (GBD) website. Data analysis was performed using Join Point software version 5.0.2 to evaluate trends in incidence and mortality.
resultsThe age-standardized incidence rate in all World Health Organization (WHO) regions was higher in women than men. This study showed that the average annual changes in the incidence of thyroid cancer increased from 1990 to 2021. The highest annual increase was observed in men and women in the Eastern Mediterranean region and the lowest in Europe. Average annual changes in mortality rates from 1990 to 2021 showed that mortality rates decreased in Europe and Africa but increased in the Eastern Mediterranean region and Southeast Asia. Projections for 2023 showed that the incidence of thyroid cancer will increase for both men and women in the Eastern Mediterranean. Meanwhile, a decreasing incidence was observed in the European region for women. Projections for 2030 showed that female mortalities would still be higher than male mortalities, except in the Western Pacific region. Also, the highest mortality in women was reported in the Eastern Mediterranean region, and in men, the Southeast Asian region showed an increasing trend.
conclusionThis study shows an increasing trend in the incidence of thyroid cancer in most regions, especially in the Eastern Mediterranean. It emphasizes that mortality in women is still higher than in men. A decrease in mortality was observed in some regions, such as Europe and Africa, but in Southeast Asia and the Eastern Mediterranean, this has been increasing. These findings highlight regional disparities in the burden of thyroid cancer and suggest that there may be a need to improve cancer surveillance and more equitable access to health services in regions with increasing trends in incidence and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.